[go: up one dir, main page]

AR111426A1 - Derivados de imidazol pentacíclico fusionado como moduladores de la actividad de tnf - Google Patents

Derivados de imidazol pentacíclico fusionado como moduladores de la actividad de tnf

Info

Publication number
AR111426A1
AR111426A1 ARP180101067A ARP180101067A AR111426A1 AR 111426 A1 AR111426 A1 AR 111426A1 AR P180101067 A ARP180101067 A AR P180101067A AR P180101067 A ARP180101067 A AR P180101067A AR 111426 A1 AR111426 A1 AR 111426A1
Authority
AR
Argentina
Prior art keywords
imidazol
modulators
tnf activity
derivatives fused
pentacyclic
Prior art date
Application number
ARP180101067A
Other languages
English (en)
Inventor
Zhaoning Zhu
Mengyang Xuan
Malcolm Maccoss
James Andrew Johnson
Martin Clive Hutchings
Helen Tracey Horsley
Yann Foricher
Haro Garcia Teresa De
Daniel Christopher Brookings
Original Assignee
Ucb Biopharma Sprl
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58632834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR111426(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl, Sanofi Sa filed Critical Ucb Biopharma Sprl
Publication of AR111426A1 publication Critical patent/AR111426A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1), o una sal farmacéuticamente aceptable del mismo, en donde X representa N o C-F; R¹ representa hidrógeno o metilo; R² representa hidrógeno, metilo o trifluorometilo; y R³ representa hidrógeno, ciano, hidroxilo o hidroximetilo.
ARP180101067A 2017-04-25 2018-04-25 Derivados de imidazol pentacíclico fusionado como moduladores de la actividad de tnf AR111426A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17168027 2017-04-25

Publications (1)

Publication Number Publication Date
AR111426A1 true AR111426A1 (es) 2019-07-10

Family

ID=58632834

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101067A AR111426A1 (es) 2017-04-25 2018-04-25 Derivados de imidazol pentacíclico fusionado como moduladores de la actividad de tnf

Country Status (32)

Country Link
US (4) US10980814B2 (es)
EP (2) EP3939980B1 (es)
JP (2) JP7083358B2 (es)
KR (1) KR102565132B1 (es)
CN (1) CN110582495B (es)
AR (1) AR111426A1 (es)
AU (1) AU2018259040B2 (es)
CA (1) CA3058980A1 (es)
CL (1) CL2019002875A1 (es)
CO (1) CO2019012856A2 (es)
CR (1) CR20190526A (es)
DK (1) DK3615534T3 (es)
EA (1) EA039049B1 (es)
ES (2) ES2893807T3 (es)
HR (1) HRP20211927T1 (es)
HU (1) HUE056593T2 (es)
IL (1) IL269890B (es)
LT (1) LT3615534T (es)
MA (2) MA49055B1 (es)
MX (1) MX2019012443A (es)
MY (1) MY197212A (es)
PE (1) PE20200662A1 (es)
PH (1) PH12019502182B1 (es)
PL (2) PL3615534T3 (es)
PT (2) PT3939980T (es)
RS (1) RS62596B1 (es)
SG (1) SG11201908871SA (es)
SI (1) SI3615534T1 (es)
TW (1) TWI801378B (es)
UY (1) UY37700A (es)
WO (1) WO2018197503A1 (es)
ZA (1) ZA201906255B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10766906B2 (en) * 2016-04-01 2020-09-08 UCB Biopharma SRL Fused hexacyclic imidazole derivatives as modulators of TNF activity
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
US11554122B2 (en) * 2018-10-24 2023-01-17 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of TNF activity
EP4622981A1 (en) 2022-11-23 2025-10-01 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
TW202508596A (zh) 2023-04-26 2025-03-01 法商賽諾菲公司 使用腫瘤壞死因子α之小分子抑制劑治療乾癬
CN121399133A (zh) * 2023-06-09 2026-01-23 上海翰森生物医药科技有限公司 五环类衍生物抑制剂、其制备方法和应用
CN121443614A (zh) 2023-07-04 2026-01-30 赛诺菲 结晶形式
WO2025038927A1 (en) 2023-08-16 2025-02-20 Raythera, Inc. Modulators of tnf alpha activity and uses thereof
WO2025068505A1 (en) 2023-09-29 2025-04-03 Sanofi Preparation of bridged pentacyclic imidazole derivatives as modulators of tnf activity, intermeditates and their preparation
WO2025201449A1 (zh) * 2024-03-27 2025-10-02 海思科医药集团股份有限公司 一种杂环衍生物及其在医药上的应用
WO2025212627A1 (en) 2024-04-03 2025-10-09 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
WO2025218735A1 (zh) * 2024-04-17 2025-10-23 上海翰森生物医药科技有限公司 五环类衍生物抑制剂、其制备方法和应用
WO2025247401A1 (zh) * 2024-05-31 2025-12-04 海思科医药集团股份有限公司 一种稠合杂环衍生物及其在医药上的应用
WO2025252251A1 (zh) * 2024-06-07 2025-12-11 上海翰森生物医药科技有限公司 含氧杂环类衍生物抑制剂、其制备方法和应用
WO2026012303A1 (en) * 2024-07-09 2026-01-15 Hangzhou Highlightll Pharmaceutical Co., Ltd NOVEL BENZO [4, 5] IMIDAZO COMPOUNDS AS TNFα MODULATORS
WO2026022134A1 (en) 2024-07-23 2026-01-29 Sanofi Novel aminocarbonylation processes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014030940B1 (pt) 2012-06-11 2022-09-06 UCB Biopharma SRL Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
ES2689429T3 (es) * 2012-07-13 2018-11-14 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de actividad de TNF
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CR20170167A (es) 2014-10-03 2017-08-10 Sanofi Sa Derivados de imidazol pentacíclicos fusionados
WO2016168641A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Tricyclic modulators of tnf signaling

Also Published As

Publication number Publication date
TWI801378B (zh) 2023-05-11
ES2956555T3 (es) 2023-12-22
AU2018259040B2 (en) 2022-04-28
JP2020517637A (ja) 2020-06-18
KR102565132B1 (ko) 2023-08-08
CN110582495B (zh) 2022-04-01
JP7299382B2 (ja) 2023-06-27
PL3615534T3 (pl) 2022-01-31
US10980814B2 (en) 2021-04-20
AU2018259040A1 (en) 2019-10-31
PH12019502182A1 (en) 2020-06-08
CL2019002875A1 (es) 2020-03-06
RS62596B1 (sr) 2021-12-31
JP7083358B2 (ja) 2022-06-10
PT3615534T (pt) 2021-10-21
CN110582495A (zh) 2019-12-17
MA57699B1 (fr) 2023-11-30
EP3615534B1 (en) 2021-09-15
ZA201906255B (en) 2021-01-27
KR20190141200A (ko) 2019-12-23
EP3939980A1 (en) 2022-01-19
EA039049B1 (ru) 2021-11-26
US20210252012A1 (en) 2021-08-19
PH12019502182B1 (en) 2024-01-31
JP2022116233A (ja) 2022-08-09
HRP20211927T1 (hr) 2022-03-18
CR20190526A (es) 2020-01-07
US20200046723A1 (en) 2020-02-13
DK3615534T3 (da) 2021-10-18
MA49055A (fr) 2021-05-05
US20250127795A1 (en) 2025-04-24
NZ758198A (en) 2024-01-26
EA201992407A1 (ru) 2020-04-06
UY37700A (es) 2018-11-30
PT3939980T (pt) 2023-08-07
US20230250105A1 (en) 2023-08-10
IL269890B (en) 2022-03-01
SG11201908871SA (en) 2019-10-30
MY197212A (en) 2023-06-01
ES2893807T3 (es) 2022-02-10
MA49055B1 (fr) 2021-12-31
PE20200662A1 (es) 2020-06-11
BR112019020314A2 (pt) 2020-04-28
CA3058980A1 (en) 2018-11-01
HUE056593T2 (hu) 2022-02-28
WO2018197503A1 (en) 2018-11-01
PL3939980T3 (pl) 2024-02-05
EP3615534A1 (en) 2020-03-04
EP3939980B1 (en) 2023-07-26
CO2019012856A2 (es) 2020-01-17
MX2019012443A (es) 2020-01-13
TW201841918A (zh) 2018-12-01
LT3615534T (lt) 2021-11-25
SI3615534T1 (sl) 2022-01-31

Similar Documents

Publication Publication Date Title
AR111426A1 (es) Derivados de imidazol pentacíclico fusionado como moduladores de la actividad de tnf
AR102977A1 (es) Inhibidores de erk
AR094911A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃
AR101367A1 (es) Pirimidinonas como inhibidores del factor xia
AR110400A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
AR102094A1 (es) Inhibidores de proteínas kras con una mutación g12c
AR090121A1 (es) Compuestos de oxazolidin-2-ona y usos de los mismos
PE20151606A1 (es) DERIVADOS DE NAFTIRIDINA UTILES COMO ANTAGONISTAS DE LA AvB6 INTEGRINA
CR20160191A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
MX374729B (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4.
CL2015002279A1 (es) Amidas heterocíclicas como inhibidores de cinasas
AR100006A1 (es) Derivados de tubulisina
MX394082B (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de cinasa pim.
AR073327A1 (es) Heterociclos nitrogenados y su uso como anticancerigenos
UY35434A (es) ?4-amino-6-(heterocíclico)picolinatos y 6-amino-2-(heterocíclico)pirimidin-4-carboxilatos y su uso como herbicidas?.
AR112333A1 (es) Pirrolopirimidina y derivados de pirrolopirimidina
AR094959A1 (es) Compuestos de imidazo piridina
AR103412A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
MX2019013194A (es) Procedimientos para preparar compuestos de tipo oxatiazina.
AR111806A1 (es) Derivados de indol n-sustituidos
AR105549A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
AR101036A1 (es) Amidas de benzoxazinona como reguladores del receptor mineralocorticoide
AR090474A1 (es) Compuestos de tetrahidropirrolotiazina
PE20150182A1 (es) Compuestos de fenoxietil piperidina
MX374383B (es) Derivados de carboxamida como inhibidores de smurf-1